These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 7514051)

  • 1. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML.
    Deisseroth AB; Zu Z; Claxton D; Hanania EG; Fu S; Ellerson D; Goldberg L; Thomas M; Janicek K; Anderson WF
    Blood; 1994 May; 83(10):3068-76. PubMed ID: 7514051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular analysis of retroviral transduction in chronic myelogenous leukemia.
    Claxton D; Suh SP; Filaccio M; Ellerson D; Gaozza E; Andersson B; Brenner M; Reading C; Feinberg A; Moen R
    Hum Gene Ther; 1991; 2(4):317-21. PubMed ID: 1665348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells.
    Talpaz M; Kantarjian H; Liang J; Calvert L; Hamer J; Tibbits P; Durett A; Claxton D; Giralt S; Khouri I
    Blood; 1995 Jun; 85(11):3257-63. PubMed ID: 7756658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo.
    Zhao RC; McIvor RS; Griffin JD; Verfaillie CM
    Blood; 1997 Dec; 90(12):4687-98. PubMed ID: 9389683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients.
    Verfaillie CM; Bhatia R; Miller W; Mortari F; Roy V; Burger S; McCullough J; Stieglbauer K; Dewald G; Heimfeld S; Miller JS; McGlave PB
    Blood; 1996 Jun; 87(11):4770-9. PubMed ID: 8639848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia.
    Kantarjian HM; Talpaz M; LeMaistre CF; Spinolo J; Spitzer G; Yau J; Dicke K; Jagannath S; Deisseroth AB
    Cancer; 1991 Jun; 67(12):2959-65. PubMed ID: 1675151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation.
    Zhang JG; Lin F; Chase A; Goldman JM; Cross NC
    Blood; 1996 Mar; 87(6):2588-93. PubMed ID: 8630427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation by bcr-abl mRNA and DNA fingerprinting.
    Okamoto R; Harano H; Matsuzaki M; Motomura S; Maruta A; Kodama F; Mohri H; Okubo T
    Am J Clin Pathol; 1995 Nov; 104(5):510-6. PubMed ID: 7572810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia.
    Roth MS; Antin JH; Ash R; Terry VH; Gotlieb M; Silver SM; Ginsburg D
    Blood; 1992 Jan; 79(1):276-82. PubMed ID: 1728316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression.
    Verfaillie CM; Miller WJ; Boylan K; McGlave PB
    Blood; 1992 Feb; 79(4):1003-10. PubMed ID: 1371077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
    Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
    Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia.
    Delage R; Soiffer RJ; Dear K; Ritz J
    Blood; 1991 Nov; 78(10):2759-67. PubMed ID: 1824268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presence of re-appearance of BCR-ABL-positive cells years after allogeneic bone marrow transplantation for chronic-phase chronic myelogenous leukemia in patients in hematological remission.
    Diekmann L; Beelen DW; Quabeck K; Becher R; Schulte Holthausen H; Bützler R; Schaefer UW; Opalka B
    Acta Haematol; 1994; 92(4):169-75. PubMed ID: 7701913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia.
    Kantarjian HM; Talpaz M; Andersson B; Khouri I; Giralt S; Rios MB; Champlin R; Hester J; Deisseroth AB
    Bone Marrow Transplant; 1994 Jul; 14(1):57-61. PubMed ID: 7951120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case report of spontaneous remission of cytogenetic relapse of chronic myelogenous leukemia suggestive of progression to blast crisis after allogeneic bone marrow transplantation.
    Agaliotis DP; Papenhausen PR; Moscinski LC; Elfenbein GJ
    Ann Hematol; 1995 Jan; 70(1):37-41. PubMed ID: 7827205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of autografting in chronic myelogenous leukemia: effects of priming regimen and marrow or blood origin of stem cells.
    Verfaillie CM; Bhatia R; Steinbuch M; DeFor T; Hirsch B; Miller JS; Weisdorf D; McGlave PB
    Blood; 1998 Sep; 92(5):1820-31. PubMed ID: 9716614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapse in chronic myeloid leukemia after bone marrow transplantation: biomathematical modeling as a new approach to understanding pathogenesis.
    Vincent PC; Rutzen-Loesevitz L; Tibken B; Heinze B; Hofer EP; Fliedner TM
    Stem Cells; 1999; 17(1):9-17. PubMed ID: 10215403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic myelogenous leukemia: molecular and cellular aspects.
    Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
    J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of bcr/abl gene in single hemopoietic progenitors in some patients with chronic myelogenous leukemia.
    Misawa M; Maeda H; Hara H; Yamamoto Y; Furuyama J
    Stem Cells; 1993 Nov; 11(6):536-42. PubMed ID: 7509222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apparent decrease and elimination of BCR/ABL mRNA-expressing residual cells in patients with chronic myelogenous leukemia after allogeneic bone marrow transplantation.
    Lange W; Herkert R; Finke J; Ragoczy U; Siegert W; Mertelsmann R; Dölken G
    Ann Hematol; 1991 Oct; 63(4):189-94. PubMed ID: 1932296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.